AveXis Company Profile (NASDAQ:AVXS)

About AveXis (NASDAQ:AVXS)

AveXis logoAveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AVXS
  • CUSIP: N/A
  • Web: www.avexis.com
Capitalization:
  • Market Cap: $3.20915 billion
  • Outstanding Shares: 31,925,000
Average Prices:
  • 50 Day Moving Avg: $96.02
  • 200 Day Moving Avg: $84.59
  • 52 Week Range: $44.68 - $106.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.70
  • P/E Growth: -1.67
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $13.83 per share
  • Price / Book: 7.23
Profitability:
  • EBITDA: ($134,280,000.00)
  • Return on Equity: -45.63%
  • Return on Assets: -42.21%
Debt:
  • Current Ratio: 15.62%
  • Quick Ratio: 15.62%
Misc:
  • Average Volume: 395,598 shs.
  • Beta: 3.05
  • Short Ratio: 10.77
 

Frequently Asked Questions for AveXis (NASDAQ:AVXS)

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

How were AveXis' earnings last quarter?

AveXis, Inc. (NASDAQ:AVXS) released its earnings results on Thursday, August, 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by $1.10. During the same quarter last year, the company earned ($0.68) EPS. View AveXis' Earnings History.

When will AveXis make its next earnings announcement?

AveXis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for AveXis.

Where is AveXis' stock going? Where will AveXis' stock price be in 2017?

16 brokers have issued 12 month price objectives for AveXis' shares. Their predictions range from $52.00 to $134.00. On average, they expect AveXis' share price to reach $106.40 in the next year. View Analyst Ratings for AveXis.

What are analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:

  • 1. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (9/7/2017)
  • 2. Jefferies Group LLC analysts commented, "Final data from AVXS-101 in SMA T1 reported that all pts in both cohorts were event free at 13.6 mo of age compared to 25% expected via natural history, the primary EP. Motor milestones were achieved with 9 pts sitting ' 5 secs and 2 pts walking independently. We have lowered our EU T1 risk adj to 15% and began including SMA T2 into our valuation with a 75% risk adj. We reiterate our Buy rating and raise our PT to $92." (3/17/2017)
  • 3. Goldman Sachs Group Inc analysts commented, "AVXS reported compelling gene therapy AVXS-101 Ph1 final results in spinal muscular atrophy (SMA, genetic neuromuscular disorder) Type I for all patients >13.6 months of age. The data continues to impress ' event-free survival (EFS, death or permanent ventilation) remains 100% in the 12 patients in the high dose therapeutic and notably, in the 3 non-therapeutic cohort as of 1/20. These results are remarkably better than the disease natural history of SMA Type I that suggests 25% EFS at 13.6 months. CHOP INTEND (motor function) and milestone improvements remain intact, with mean increase from baseline of +24.7 (vs. +24.8 prior) in the therapeutic dose vs. -10.5/yr per natural history. 11 (92%) patients are sitting unassisted (by definition, SMA Type I patients never sit unassisted), 9 (75%) rolling over, 2 (17%) standing alone and 2 (17%) walking independently, in line with prior 3m data. On the safety front, SAEs remain restricted to prior asymptomatic liver enzyme elevations which resolved with steroids. We look to: (1) the May 1 FDA meeting (vs. Mar) to discuss the manufacturing (CMC) outlook and June update post receipt of minutes; and (2) an end-of-Ph1 meeting with the FDA in 2Q/3Q to discuss a potential accelerated approval, which would provide upside to our estimates (we assume a 2020 launch on Ph3 data, GSe peak sales of $927mn)." (3/17/2017)
  • 4. Chardan Capital analysts commented, "On 23 December 2016, partners Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS)), announced the US FDA approved Spinraza (nusinersen), a chronically-administered SMN2 antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA) types 1 to 3. As discussed in our 27 December 2016 note, on efficacy, Figure 1 of the Spinraza label shows that 23% of SMA type 1 patients taking Spinraza died compared to 43% of untreated patients. We compare this to the phase I trial of AAV-based gene therapy (GT) AVXS-101 (a one-time treatment) from AveXis (Buy), where no SMA type 1 patients so far have died. On safety, as discussed in our 17 January 2017 industry note, the Spinraza label states that 11% of patients developed a platelet level below the lower limit of normal, compared to 0% of patients under sham treatment. Furthermore, as covered in both our 23 January 2017 industry note and in today's accompanying industry note, "Spinraza FDA review confirms our concerns of antisense platelet class effects", both Anthem Healthcare (unrated) and the FDA have expressed concerns regarding the safety of Spinraza."He added, "Considering the above efficacy and safety issues for Spinraza relative to AVXS-101, we reiterate our AVXS Buy rating, make AVXS a Chardan top pick for 2017, and increase our AVXS PT from $85 to $100 (+18%). We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch." (1/26/2017)

Who are some of AveXis' key competitors?

Who are AveXis' key executives?

AveXis' management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board
  • Sean Patrick Nolan, President, Chief Executive Officer, Director
  • Thomas J. Dee, Chief Financial Officer, Senior Vice President
  • Lori J. Smith, Chief Human Resource Officer, Senior Vice President
  • Michael Johannesen, Senior Vice President, Chief Compliance Officer, General Counsel
  • Andrew F. Knudten, Senior Vice President - Manufacturing and Supply Chain
  • James J. L'Italien Ph.D., Senior Vice President - Chief Regulatory and Quality Officer
  • Rick Modi, Senior Vice President, Chief Business Officer
  • Sukumar Nagendran, Senior Vice President and Chief Medical Officer
  • R. A. Session II, Senior Vice President - Corporate Strategy and Project Management

When did AveXis IPO?

(AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Who owns AveXis stock?

AveXis' stock is owned by a number of of retail and institutional investors. Top institutional investors include FLYNN JAMES E (7.28%) and Deschutes Portfolio Strategy LLC (0.01%). Company insiders that own AveXis stock include Bong Y Koh, Brian K Kaspar, James E Flynn, Paul B Manning and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

Who bought AveXis stock? Who is buying AveXis stock?

AveXis' stock was bought by a variety of institutional investors in the last quarter, including Deschutes Portfolio Strategy LLC. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn. View Insider Buying and Selling for AveXis.

How do I buy AveXis stock?

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AveXis' stock price today?

One share of AveXis stock can currently be purchased for approximately $100.06.


MarketBeat Community Rating for AveXis (NASDAQ AVXS)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AveXis (NASDAQ:AVXS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $106.40 (6.34% upside)
Consensus Price Target History for AveXis (NASDAQ:AVXS)
Price Target History for AveXis (NASDAQ:AVXS)
Analysts' Ratings History for AveXis (NASDAQ:AVXS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017BMO Capital MarketsReiterated RatingOutperform$123.00 -> $130.00N/AView Rating Details
10/12/2017Jefferies Group LLCBoost Price TargetBuy$118.00N/AView Rating Details
10/6/2017Goldman Sachs Group IncReiterated RatingBuy -> Buy$130.00N/AView Rating Details
10/2/2017Citigroup Inc.Boost Price TargetBuy$100.00 -> $116.00LowView Rating Details
9/29/2017Wells Fargo & CompanyReiterated RatingOutperformHighView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$92.00HighView Rating Details
9/6/2017Barclays PLCInitiated CoverageOverweight$124.00LowView Rating Details
8/29/2017InstinetInitiated CoverageReduce -> Reduce$52.00LowView Rating Details
8/28/2017NomuraInitiated CoverageReduce$52.00HighView Rating Details
8/23/2017William BlairInitiated CoverageOutperform -> Outperform$107.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$120.00MediumView Rating Details
8/11/2017Chardan CapitalReiterated RatingBuy -> Buy$102.50 -> $130.00MediumView Rating Details
8/9/2017Morgan StanleyReiterated RatingOverweight$118.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$108.00MediumView Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/AView Rating Details
10/21/2016Bank of America CorporationInitiated CoverageBuyN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for AveXis (NASDAQ:AVXS)
Earnings by Quarter for AveXis (NASDAQ:AVXS)
Earnings History by Quarter for AveXis (NASDAQ AVXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($1.48)N/AView Earnings Details
8/10/2017Q2 2017($0.97)($2.07)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.95)($1.07)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)($0.92)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.70)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AveXis (NASDAQ:AVXS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($1.35)($1.35)($1.35)
Q4 20171($1.39)($1.39)($1.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AveXis (NASDAQ:AVXS)
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 94.71%
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2017Brian K KasparInsiderSell15,000$101.46$1,521,900.00View SEC Filing  
10/2/2017Sukumar NagendranVPSell1,780$97.25$173,105.00View SEC Filing  
9/1/2017Sukumar NagendranVPSell1,780$93.25$165,985.00View SEC Filing  
8/1/2017Sukumar NagendranVPSell1,780$91.52$162,905.60View SEC Filing  
7/3/2017Sukumar NagendranVPSell1,780$81.88$145,746.40View SEC Filing  
6/1/2017Sukumar NagendranVPSell1,780$70.91$126,219.80View SEC Filing  
5/1/2017Sukumar NagendranVPSell1,780$81.39$144,874.20View SEC Filing  
4/3/2017Sukumar NagendranVPSell1,781$76.13$135,587.53View SEC Filing  
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AveXis (NASDAQ:AVXS)
Latest Headlines for AveXis (NASDAQ:AVXS)
Source:
DateHeadline
americanbankingnews.com logoFY2018 EPS Estimates for AveXis, Inc. Lifted by Jefferies Group (AVXS)
www.americanbankingnews.com - October 16 at 7:56 AM
americanbankingnews.com logoAveXis, Inc. (AVXS) Given New $118.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - October 15 at 8:54 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms "Outperform" Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - October 12 at 9:46 AM
americanbankingnews.com logoAveXis, Inc. (AVXS) Insider Sells $1,521,900.00 in Stock
www.americanbankingnews.com - October 11 at 7:30 PM
thestreet.com logoShort Interest Decreases By 16.8% For AVXS
www.thestreet.com - October 11 at 5:48 PM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Reiterates Buy Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - October 7 at 12:58 AM
americanbankingnews.com logoSukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock
www.americanbankingnews.com - October 3 at 11:14 PM
reuters.com logoBRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101
www.reuters.com - October 3 at 3:58 PM
finance.yahoo.com logoFeatured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis
finance.yahoo.com - October 3 at 3:58 PM
finance.yahoo.com logoAveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society
finance.yahoo.com - October 3 at 3:58 PM
finance.yahoo.com logoAveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data
finance.yahoo.com - October 3 at 3:58 PM
americanbankingnews.com logoAveXis' (AVXS) Buy Rating Reaffirmed at UBS AG
www.americanbankingnews.com - October 3 at 8:41 AM
finance.yahoo.com logo[$$] Gene Therapy Is Nearing a Major Breakthrough
finance.yahoo.com - October 2 at 4:08 PM
finance.yahoo.com logoAveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
finance.yahoo.com - October 2 at 4:08 PM
finance.yahoo.com logoAveXis: Now That's a Go Ahead!
finance.yahoo.com - October 2 at 4:08 PM
globenewswire.com logoAveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial ... - GlobeNewswire (press release)
globenewswire.com - September 30 at 11:55 PM
reuters.com logoBRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1
www.reuters.com - September 30 at 1:51 PM
americanbankingnews.com logoBMO Capital Markets Reiterates Outperform Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - September 30 at 1:10 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 12:44 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Earns "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - September 29 at 1:31 PM
americanbankingnews.com logoRoyal Bank Of Canada Begins Coverage on AveXis, Inc. (AVXS)
www.americanbankingnews.com - September 14 at 11:06 PM
nasdaq.com logoNotable Thursday Option Activity: NFLX, AVXS, ICPT
www.nasdaq.com - September 14 at 4:51 PM
finance.yahoo.com logoBreaking Down Barclays' New Bullish Calls On Biotech
finance.yahoo.com - September 7 at 9:19 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Coverage Initiated at Barclays PLC
www.americanbankingnews.com - September 6 at 5:18 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) VP Sukumar Nagendran Sells 1,780 Shares
www.americanbankingnews.com - September 5 at 8:06 PM
marketwatch.com logoHow investors should play gene-therapy stocks
www.marketwatch.com - September 5 at 5:49 PM
americanbankingnews.com logoWells Fargo & Company Reiterates Outperform Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - September 5 at 3:34 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 2:58 PM
streetinsider.com logoPre-Open Movers 08/29: (MOV) (CTLT) (IMGN) Higher; (FINL) (ACOR) (JILL) Lower (more...)
www.streetinsider.com - August 29 at 9:32 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Now Covered by Analysts at Instinet
www.americanbankingnews.com - August 29 at 8:20 PM
americanbankingnews.com logoNomura Begins Coverage on AveXis, Inc. (AVXS)
www.americanbankingnews.com - August 28 at 9:24 PM
americanbankingnews.com logoQ3 2017 Earnings Estimate for AveXis, Inc. (AVXS) Issued By William Blair
www.americanbankingnews.com - August 25 at 8:30 AM
nasdaq.com logoCommit To Purchase AveXis At $80, Earn 16.5% Annualized Using Options
www.nasdaq.com - August 24 at 9:19 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Now Covered by Analysts at William Blair
www.americanbankingnews.com - August 23 at 9:30 AM
americanbankingnews.com logoEvercore ISI Begins Coverage on AveXis, Inc. (AVXS)
www.americanbankingnews.com - August 16 at 6:26 PM
americanbankingnews.com logo Brokerages Expect AveXis, Inc. (NASDAQ:AVXS) to Announce -$0.94 EPS
www.americanbankingnews.com - August 14 at 8:04 PM
americanbankingnews.com logoAveXis, Inc. (NASDAQ:AVXS) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - August 13 at 9:08 PM
seekingalpha.com logoAveXis' (AVXS) CEO Sean Nolan on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 3:58 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for AveXis, Inc. (NASDAQ:AVXS)
www.americanbankingnews.com - August 11 at 7:22 PM
americanbankingnews.com logoAveXis, Inc. (NASDAQ:AVXS) Price Target Raised to $130.00
www.americanbankingnews.com - August 11 at 5:36 PM
finance.yahoo.com logoEdited Transcript of AVXS earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 4:44 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 11 at 3:22 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Announces Earnings Results
www.americanbankingnews.com - August 10 at 9:35 PM
reuters.com logoBRIEF-AveXis reports Q2 loss per share $2.07
www.reuters.com - August 10 at 9:12 PM
finance.yahoo.com logoAveXis Reports Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - August 10 at 4:07 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) VP Sells $162,905.60 in Stock
www.americanbankingnews.com - August 3 at 8:40 PM
finance.yahoo.com logoAveXis to Report Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - August 3 at 5:40 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM
americanbankingnews.com logoAveXis, Inc. (NASDAQ:AVXS) Expected to Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - July 27 at 4:25 PM
finance.yahoo.com logoAveXis Inc.: Buy at the High?
finance.yahoo.com - July 26 at 2:14 AM

Social

Chart

AveXis (AVXS) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.